Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …

Myelodysplastic syndromes (MDS) are malignant clonal disorders of haematopoietic stem
cells and their microenvironment, affecting older individuals (median age∼ 70 years) …

Bone marrow CD34+ cell apoptosis (annexin V), proliferation (Ki-67), and Bcl-2-related
protein expression was evaluated by flow cytometry in 102 patients with myelodysplastic …

The myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency
associated with cytopenias leading to serious morbidity plus the additional risk of leukemic …

Immunological responses are increasingly recognised as being important in the initiation
and progression of myelodysplastic syndrome (MDS). Indeed, autoimmune diseases …

The myelodysplastic syndrome (MDS) includes a diverse group of clonal and potentially
malignant bone marrow disorders characterized by ineffective and inadequate …

Arsenic trioxide (ATO) has a long history of efficacy as an antileukemic agent. However, with
the advent of modern therapy, it had been relegated to a historical footnote. In the 1990s …

The myelodysplastic syndromes (MDSs) are collections of heterogeneous hematologic
diseases characterized by refractory cytopenias as a result of ineffective hematopoiesis …

Recent advances in molecular genetics have advanced the knowledge regarding the
mechanisms leading to myelodysplastic syndrome (MDS), secondary acute myeloid …

Myelodysplastic syndromes (MDS) are characterized by peripheral blood cytopenias despite
hypercellularity of the bone marrow regarded as the result of ineffective hematopoiesis …